Results 101 to 110 of about 2,463,575 (352)
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Patient Safety and Patients' Rights [PDF]
AMA Journal of Ethics, 2004 Patient safety can be improved through the implementation of a physician reporting system, in which medical errors can be reported confidentially. Virtual Mentor is a monthly bioethics journal published by the American Medical Association.
openaire +2 more sources
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes [PDF]
, 2009 Tina Vilsbøll +12 more
openalex +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Risky Business: Peripheral and Central Venous Catheters Both Pose Risks
Patient Safety, 2019 Venous access is an essential method of providing life-saving therapy. As part of intensive efforts to decrease the incidence of central line–associated bloodstream infections (CLABSIs), healthcare facilities may be increasing the use of short ...
Lynette Hathaway, Mary C. Magee
doaj +1 more source
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial [PDF]
, 2018 Christina Fanola +11 more
openalex +1 more source
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Molecular Oncology, EarlyView.Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source
Results of the Patient Safety Authority’s 2018 Process Measures Survey
Patient Safety, 2019 Improving patient safety is an ongoing journey that benefits from periodic assessment to recognize, reward, and redirect efforts. As an independent, nonregulatory state agency, the Patient Safety Authority (PSA) is uniquely positioned to both conduct ...
Michelle Bell, Kim Liberatore
doaj +1 more source
Safety Rounds: A Patient Safety Initiative
The Canadian Journal of Hospital Pharmacy, 2019 -
Heather, Kertland +4 more
openaire +3 more sources
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Molecular Oncology, EarlyView.Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source